Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Gets CLIA Certification for California Lab

NEW YORK (GenomeWeb News) – Dutch molecular diagnostics firm Agendia has received Clinical Laboratory Improvement Amendments certification for its newly opened lab in Huntington Beach, Calif.

The firm has opened the lab to help drive US adoption of its MammaPrint breast cancer diagnostic test. Agendia received US Food and Drug Administration clearance of the array-based test two years ago and had been working with reference centers in the US to help drive sales. MammaPrint was the first IVDMIA microarray-based diagnostic test to be cleared by the FDA.

"Our enhanced domestic capabilities will help us to further drive adoption of MammaPrint, and place us in an even better position to collaborate with a growing number of clinical, academic, and industrial partners here in the US," Agendia President and CEO Bernhard Sixt said in a statement.

Agendia also operates a CLIA-certified lab in its home base of Amsterdam.

Filed under

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.